Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.61 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.61 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19866987 | 1.00 | CD274 (0.61) | CD274VSIRPDCD1LG2PDCD1MMP12 | |
| SCHEMBL18077975 | 1.00 | CD274 (0.61) | CD274VSIRPDCD1LG2PDCD1MMP12 | |
| SCHEMBL18077940 | 0.91 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19866981 | 0.91 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL18077963 | 0.91 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19867028 | 0.91 | CD274 (0.64) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19867082 | 0.90 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL19867020 | 0.90 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL18077976 | 0.90 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1 | |
| SCHEMBL18077927 | 0.90 | CD274 (0.63) | CD274VSIRPDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577306-A1 | COMBINATION CANCER TREATMENT COMPRISING AN ANTI-MSLN/CD137 ANTIBODY AND PD-1/PD-L1 INHIBITOR | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-119836302-A | Combination cancer treatment comprising anti-MSLN/CD 137 antibodies and PD-1/PD-L1 inhibitors | 默克专利股份公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2024042104-A1 | COMBINATION CANCER TREATMENT COMPRISING AN ANTI-MSLN/CD137 ANTIBODY AND PD-1/PD-L1 INHIBITOR | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |